Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewAlmirall at the JPMorgan Conference - entering a new era of sustained growth
"2025 is a turning point for Almirall as we are entering an era of sustained double-digit growth of our net sales CAGR to 2030, and increased EBITDA margins to around 25% by 2028," stated Carlos
-
-
NewSurveillance and diagnosis of influenza and other seasonal respiratory viruses
Although respiratory diseases are generally not severe, they cause thousands of hospitalizations and deaths worldwide every year, which would increase dramatically if surveillance systems were not in
-
EventBio International Convention 2025
AseBio participates in the official Spanish pavilion organized by ICEX (Spanish Institute of Foreign Trade).
-
CompanyDANAGEN BIOTED
-
NewORYZON announces first patient dosed in NCI-sponsored iadademstat in combination with vene...
Study conducted under the CRADA agreement between NCI and Oryzon.
-
EventSwiss Biotech Day 2025
AseBio participates in the Global Village as part of ICEX's internationalization plan
-
-
NewBCN HEALTH publishes a study assessing the epidemiological situation and cost of Alzheimer...
The medical costs of Alzheimer's disease in hospital care increased during the study period, with an average annual cost per patient of 4,969 euros.
-
-
NewORYZON to provide corporate progress updates at several events in January-February
Among these, the following stand out 8º Sachs Annual Neuroscience Innovation Forum, 14º Annual LifeSci Advisors Corporate Access Event, Invest Securities BioMed Forum 2025, MidCap Event Frankfurt 2025
-
New#NewAseBioMember | “AseBio is a key player in the growth of biotechnology in Spain”
Meet Grupo AIA, our new member. We spoke with Guillermo Rodriguez Lázaro, Chief Scientific Director.
-
CompanySERVATRIX BIOMED
-
NewKey Trends in Sepsis for 2025
In Spain, the incidence of sepsis is 212 cases per 100,000 inhabitants per year, with a mortality rate ranging from 15% to 50%, depending on the severity and speed of treatment.
-
CompanyNET PHARMA
-
-
-
EventISCT 2025
-
-
-